JP2017523789A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523789A5
JP2017523789A5 JP2017506395A JP2017506395A JP2017523789A5 JP 2017523789 A5 JP2017523789 A5 JP 2017523789A5 JP 2017506395 A JP2017506395 A JP 2017506395A JP 2017506395 A JP2017506395 A JP 2017506395A JP 2017523789 A5 JP2017523789 A5 JP 2017523789A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
polypeptide
subject
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506395A
Other languages
English (en)
Japanese (ja)
Other versions
JP6723982B2 (ja
JP2017523789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043792 external-priority patent/WO2016022671A1/en
Publication of JP2017523789A publication Critical patent/JP2017523789A/ja
Publication of JP2017523789A5 publication Critical patent/JP2017523789A5/ja
Application granted granted Critical
Publication of JP6723982B2 publication Critical patent/JP6723982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506395A 2014-08-06 2015-08-05 インターロイキン−2/インターロイキン−2受容体アルファ融合タンパク質および使用方法 Active JP6723982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
US62/033,726 2014-08-06
PCT/US2015/043792 WO2016022671A1 (en) 2014-08-06 2015-08-05 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020108721A Division JP7272663B2 (ja) 2014-08-06 2020-06-24 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法

Publications (3)

Publication Number Publication Date
JP2017523789A JP2017523789A (ja) 2017-08-24
JP2017523789A5 true JP2017523789A5 (OSRAM) 2018-09-13
JP6723982B2 JP6723982B2 (ja) 2020-07-15

Family

ID=53836871

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017506395A Active JP6723982B2 (ja) 2014-08-06 2015-08-05 インターロイキン−2/インターロイキン−2受容体アルファ融合タンパク質および使用方法
JP2020108721A Active JP7272663B2 (ja) 2014-08-06 2020-06-24 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法
JP2023069282A Pending JP2023099045A (ja) 2014-08-06 2023-04-20 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020108721A Active JP7272663B2 (ja) 2014-08-06 2020-06-24 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法
JP2023069282A Pending JP2023099045A (ja) 2014-08-06 2023-04-20 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法

Country Status (32)

Country Link
US (3) US12084483B2 (OSRAM)
EP (2) EP3177307B1 (OSRAM)
JP (3) JP6723982B2 (OSRAM)
KR (1) KR102653758B1 (OSRAM)
CN (2) CN113912737A (OSRAM)
AU (3) AU2015301071C1 (OSRAM)
BR (1) BR112017001940A2 (OSRAM)
CA (1) CA2957273C (OSRAM)
CL (1) CL2017000284A1 (OSRAM)
CO (1) CO2017002166A2 (OSRAM)
DK (1) DK3177307T3 (OSRAM)
EA (2) EA035956B1 (OSRAM)
ES (1) ES2986097T3 (OSRAM)
FI (1) FI3177307T3 (OSRAM)
HR (1) HRP20241258T1 (OSRAM)
HU (1) HUE068478T2 (OSRAM)
IL (2) IL250007B (OSRAM)
LT (1) LT3177307T (OSRAM)
MA (2) MA40094B1 (OSRAM)
MX (1) MX388977B (OSRAM)
MY (1) MY180831A (OSRAM)
PE (1) PE20170503A1 (OSRAM)
PH (1) PH12017500042A1 (OSRAM)
PT (1) PT3177307T (OSRAM)
RS (1) RS65930B1 (OSRAM)
SA (1) SA517380842B1 (OSRAM)
SG (2) SG11201700706WA (OSRAM)
SI (1) SI3177307T1 (OSRAM)
SM (1) SMT202400414T1 (OSRAM)
TN (1) TN2017000020A1 (OSRAM)
WO (1) WO2016022671A1 (OSRAM)
ZA (1) ZA201700245B (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
PE20161324A1 (es) 2014-02-06 2016-11-25 Hoffmann La Roche Proteinas de fusion de interleucina-2 y usos de las mismas
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
CN109689694B (zh) * 2016-05-19 2022-11-22 通用医疗公司 与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台
BR112019005944A2 (pt) 2016-09-28 2019-06-11 Musc Foudation For Res Development anticorpos que se ligam à interleucina 2 e usos dos mesmos
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CA3084262A1 (en) * 2017-12-06 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
EP3768700A1 (en) 2018-03-23 2021-01-27 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
US11359000B2 (en) * 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
MX2021011258A (es) * 2019-03-18 2021-12-10 Biontech Cell & Gene Therapies Gmbh Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activacion especifica de celulas efectoras inmunitarias.
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. MADCAM TARGETED IMMUNOTLERANCE
JP2022533254A (ja) * 2019-05-24 2022-07-21 プロヴィヴァ セラピューティクス (ホン コン) リミテッド Il-2組成物およびその使用方法
US20210038684A1 (en) * 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
CN114450297A (zh) * 2019-07-12 2022-05-06 普罗维瓦疗法香港有限公司 Il-2组合物及其使用方法
BR112022001320A2 (pt) * 2019-07-25 2022-04-12 Univ Chicago Composições e métodos compreendendo agentes terapêuticos ativados por protease
WO2021055568A1 (en) * 2019-09-19 2021-03-25 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
CN114555110A (zh) * 2019-10-18 2022-05-27 奥克梅斯制药爱尔兰有限公司 与免疫检查点抑制剂组合的免疫调节性il-2剂
US20210188934A1 (en) * 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN115996946A (zh) 2020-04-30 2023-04-21 免疫靶向有限公司 可活化il2组合物和使用方法
CN116194480A (zh) * 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
CA3243480A1 (en) * 2022-02-11 2023-08-17 Mural Oncology Inc CANCER IMMUNOTHERAPY COMPOSITIONS AND METHODS
US20250154216A1 (en) * 2022-02-16 2025-05-15 University Of Miami Il-2 and tl1a fusion proteins and methods of use thereof
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
KR20250152067A (ko) * 2023-02-22 2025-10-22 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-il2ra 항체 및 이의 용도
WO2025207491A1 (en) * 2024-03-25 2025-10-02 Mural Oncology, Inc. Compositions and methods for cancer immunotherapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
WO1996020219A2 (en) 1994-12-28 1996-07-04 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
WO2003029475A1 (fr) * 2001-09-28 2003-04-10 Dnavec Research Inc. Vecteur viral infectant une cellule de mammifere, codant pour la $g(b)2m liee a un epitope
AU2005227263A1 (en) 2004-03-05 2005-10-06 Novartis Vaccines And Diagnostics, Inc. In vitro test system for predicting patient tolerability of therapeutic agents
PL1899364T5 (pl) * 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
CN101255197B (zh) 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
US8734774B2 (en) * 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
WO2012088383A2 (en) 2010-12-23 2012-06-28 Genentech, Inc. PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME
WO2013184938A2 (en) * 2012-06-08 2013-12-12 Alkermes. Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Similar Documents

Publication Publication Date Title
JP2017523789A5 (OSRAM)
FI3177307T3 (fi) Interleukiini-2/interleukiini-2-reseptori alfa-fuusioproteiinit ja niiden käyttömenetelmät
US12285462B2 (en) pH-triggered membrane peptide-mediated epitope tethering at cell surfaces
CA3086842A1 (en) Il-2 variant
RU2017101436A (ru) Mic-1 слитные белки и их применение
JP2014525901A5 (OSRAM)
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
HRP20161450T1 (hr) Stabilizirana varijanta aktivinskog receptora iib
CN109689086A (zh) 具有延长的血清半衰期的融合蛋白
JP2015524413A5 (OSRAM)
JP2014510519A5 (OSRAM)
JP2015511599A5 (OSRAM)
CN107698684A (zh) 包含突变的免疫球蛋白Fc部分的GLP‑1融合蛋白
NZ760008A (en) Uti fusion proteins
RU2010141916A (ru) Растворимый мутант рецептора фактора некроза опухоли
JP2010535504A5 (OSRAM)
JP6320973B2 (ja) B細胞活性化因子の拮抗物質、その調製方法及び利用法
AU2018200638A1 (en) Immunotherapeutic composition, therapeutic method and diagnostic method
WO2023071390A1 (zh) 一种重组白介素-15变体
CN116375880A (zh) 融合蛋白及其制备方法和应用
US20100055135A1 (en) Enhancin of hepatitis b virus vaccine and its gene
CN117384298A (zh) 一种快速规模化生产病毒样颗粒疫苗或药物的方法
CN103145854A (zh) 重组Tβ4-BP5融合肽、基因、工程菌及应用
RU2850342C1 (ru) Индивидуализированная терапевтическая противораковая вакцина
JP2015514082A (ja) オステオプロテゲリン由来の組成物およびその使用